<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02941523</url>
  </required_header>
  <id_info>
    <org_study_id>NOX66-001A</org_study_id>
    <nct_id>NCT02941523</nct_id>
  </id_info>
  <brief_title>Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours</brief_title>
  <official_title>Phase Ia/Ib and Potential Phase IIa Study of the Safety and Pharmacokinetics of NOX66 Both as a Monotherapy and in Combination With Carboplatin in Patients With Refractory Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Noxopharm Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Noxopharm Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the safety and activity of NOX66 in patients with refractory solid tumors&#xD;
      that are non responsive to standard therapies.&#xD;
&#xD;
      This is a two part with a potential third part, open-label, multicenter, dose escalation&#xD;
      study of NOX66 as monotherapy and in combination with carboplatin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idronoxil is a synthetic small molecule that pre-clinical studies have identified as a strong&#xD;
      candidate for development as a chemo-sensitising drug.&#xD;
&#xD;
      Human studies using idronoxil administered in oral and intravenous dosage forms have shown&#xD;
      that the drug is highly susceptible to Phase 2 metabolism, resulting in loss of bio-activity.&#xD;
&#xD;
      NOX66 is idronoxil in a new dosage formulation developed specifically to protect the drug&#xD;
      from Phase 2 metabolism and thereby ensure retention of the majority of administered drug in&#xD;
      a bio-active form.&#xD;
&#xD;
      The main purpose of the current study is to confirm the safety of the new dosage formula both&#xD;
      as a monotherapy and in combination with carboplatin, given that it is anticipated that the&#xD;
      drug will be present in the body in a bio-active form at considerably higher levels than&#xD;
      previously achieved.&#xD;
&#xD;
      A secondary objective is to observe if NOX66 is able to restore response to carboplatin in&#xD;
      tumours considered unresponsive to this chemotherapy, and moreover to provide a meaningful&#xD;
      clinical benefit in combination with a lower-than-normal dosage of carboplatin.&#xD;
&#xD;
      Patients will be drawn from 5 cancer types: prostate cancer, lung cancer, breast cancer,&#xD;
      ovarian cancer, head and neck cancer.&#xD;
&#xD;
      The study will commence with a Phase 1a (Run-in) arm comparing the relative tolerability and&#xD;
      safety of two different dosages of idronoxil/NOX66 as a 14-day monotherapy course.&#xD;
&#xD;
      Providing there is no dose limiting toxicity (DLT), patients then progress onto the Phase 1b&#xD;
      (Combination) arm of the study, remaining on the same dosage. In this arm, patients receive 6&#xD;
      treatment cycles, each of 28 days comprising NOX66 (idronoxil) treatment on Days 1-7 and&#xD;
      carboplatin on Day 2 of each treatment cycle.&#xD;
&#xD;
      Any meaningful clinical responses occurring in the Phase 1b (Combination) Arm will trigger a&#xD;
      Phase IIa (Combination) Arm where an additional 10 patients will be recruited into a maximum&#xD;
      of 2 cohorts of the same tumour type (prostate, lung, breast, ovarian, or head and neck).&#xD;
      These patients will receive the same combination dosage providing the observed clinical&#xD;
      responses and treated with that dosage for a maximum of 6 treatment cycles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 3, 2017</start_date>
  <completion_date type="Actual">January 10, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experience Dose Limiting Toxicity (DLT) During NOX66 Monotherapy and During NOX66 Combination With Carboplatin</measure>
    <time_frame>Up to 1 month for NOX66 monotherapy from enrollment and up to 7 months from start of NOX66 combination therapy</time_frame>
    <description>Dose limiting toxicity during monotherapy and combination therapy defined as any Grade 3 or more toxicity (by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE version 4.03]) (related to therapy) excluding Grade 3 or more neutropenia lasting greater than 5 days or thrombocytopenia associate with bleeding or Grade 4 thrombocytopenia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Treatment Emergent Adverse Events (SAEs) Related to NOX66.</measure>
    <time_frame>From enrollment through 30 days after the last cycle of therapy (8 months)</time_frame>
    <description>An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug that were absent before treatment or that worsened relative to pre-treatment state. Treatment-related are events which had causal relationship to study drug as assessed by the Investigator and were suspected to be reasonably related to the study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) at Cycle 3 and at Cycle 6 of Combination Therapy</measure>
    <time_frame>Radiological evaluation at baseline and at 3 months and at 6 months</time_frame>
    <description>Objective response rate defined as the percentage of participants achieving a complete response (CR) and or partial response (PR) after treatment with NOX66 and carboplatin therapy as assessed by Response Evaluation Criteria in solid tumors (RECIST) v1.1.&#xD;
CR defined as disappearance of all target and non-target lesions and reduction of any pathological lymph nodes (whether target or non-target) to &lt;10 mm in short axis; PR was defined by a 30% or more decrease in sum of longest diameter (SLD) of target lesions in reference to baseline. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and no new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Clinical Response Rate at Cycle 3 and at Cycle 6 of Combination Therapy</measure>
    <time_frame>Radiological evaluation at baseline and at 3 months and at 6 months</time_frame>
    <description>Overall Clinical response rate defined as the percentage of participants who achieved complete response (CR) or partial response (PR) or stable disease (SD) as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) criteria v1.1 after combination of NOX66 and carboplatin therapy.&#xD;
CR defined as disappearance of all target and non-target lesions and reduction of any pathological lymph nodes (whether target or non-target) to &lt;10 mm in short axis; PR was defined by a 30% or more decrease in sum of longest diameter (SLD) of target lesions in reference to baseline. Stable disease (SD)=Neither sufficient increase to qualify for PD nor sufficient shrinkage to qualify for PR. PD was defined as at least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>1a NOX66</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NOX66 administered daily for 14 day in a 21-day treatment cycle. NOX66 treatment given to two cohorts of patients as 1 of 2 dose regimens:&#xD;
Regimen 1: 400 mg; Regimen 2: 800 mg (idronoxil)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1b NOX66 and Carboplatin (combined)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NOX66 administered on Days 1-7 and carboplatin IV infusion on Day 2 of each 28-day treatment cycle up to 6 cycles.&#xD;
NOX66 at the same dosage received in the Run-In Arm combined with 2 carboplatin doses starting with low dose carboplatin AUC = 4 for treatment cycles 1-3 followed by higher dose carboplatin AUC = 6 for treatment cycles 4-6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2a NOX66 and Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm triggered by observed meaningful clinical responses from the 1b Combination Arm in particular disease indications.&#xD;
Treatment NOX66 + carboplatin administered over 6 cycles each of 28-days at observed clinical response dosage. A maximum of 2 cohorts, each comprising patients with specific tumour type.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NOX66</intervention_name>
    <description>NOX66 administration</description>
    <arm_group_label>1a NOX66</arm_group_label>
    <arm_group_label>1b NOX66 and Carboplatin (combined)</arm_group_label>
    <arm_group_label>2a NOX66 and Carboplatin</arm_group_label>
    <other_name>Idronoxil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin administration</description>
    <arm_group_label>1b NOX66 and Carboplatin (combined)</arm_group_label>
    <arm_group_label>2a NOX66 and Carboplatin</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of informed consent&#xD;
&#xD;
          2. Male or female ≥18 years of age&#xD;
&#xD;
          3. Histologic or cytologic confirmed locally advanced or metastatic cancer that has no&#xD;
             standard therapeutic alternatives.&#xD;
&#xD;
          4. ECOG Performance status 0-1&#xD;
&#xD;
          5. A minimum life expectancy of 12 weeks&#xD;
&#xD;
          6. Adequate bone marrow, hepatic and renal function as evidenced by:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &gt; 1.5 x 109/L&#xD;
&#xD;
               -  Platelet count &gt; 100 x 109/L&#xD;
&#xD;
               -  Hemoglobin &gt; 9.0 g/dL&#xD;
&#xD;
               -  Serum bilirubin &lt; 1.5 x ULN&#xD;
&#xD;
               -  AST/ALT (SGOT/SGPT) 2.5 x ULN for the reference laboratory or &lt; 5 x ULN in the&#xD;
                  presence of liver metastases&#xD;
&#xD;
               -  Serum creatinine 1.5 x ULN&#xD;
&#xD;
          7. Female patients who are known to be capable of conception should have a negative serum&#xD;
             pregnancy test (beta-human chorionic gonadotropin (β-hCG)) within 1 week of starting&#xD;
             the study&#xD;
&#xD;
          8. All potentially fertile patients will agree to use an effective form of contraception&#xD;
             during the study and for 90 days following the last dose of NOX66 (an effective form&#xD;
             of contraception is defined as an oral contraceptive or a double barrier method&#xD;
&#xD;
          9. At least 4 weeks must have elapsed prior to commencement of NOX66 treatment since&#xD;
             prior chemotherapy, investigational drug or biologic therapy and any toxicity&#xD;
             associated with these treatments has recovered to ≤ NCI-CTCAE Grade 1&#xD;
&#xD;
         10. At least 21 days must have elapsed prior to Day 1 Cycle 1 since radiotherapy (limited&#xD;
             palliative radiation is allowed &gt; 2 weeks), immunotherapy or following major surgery&#xD;
             and any surgical incision should be completely healed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are pregnant or breastfeeding.&#xD;
&#xD;
          2. Uncontrolled infection or systemic disease.&#xD;
&#xD;
          3. Clinically significant cardiac disease not well controlled with medication (e.g.&#xD;
             congestive heart failure, symptomatic coronary artery disease, angina, and cardiac&#xD;
             arrhythmias) or myocardial infarction within the last 12 months.&#xD;
&#xD;
          4. Patients with QTc of &gt; 470 msec on screening ECG. (If a patient has QTc interval &gt;470&#xD;
             msec on screening ECG, the screening ECG may be repeated twice (at least 24 hours&#xD;
             apart). The average QTc from the 3 screening ECGs must be &lt;470 msec in order for the&#xD;
             patient to be eligible for the study.&#xD;
&#xD;
          5. Any major surgery, radiotherapy, or immunotherapy within the last 21 days (limited&#xD;
             palliative radiation is allowed &gt; 2 weeks).&#xD;
&#xD;
          6. Chemotherapy regimens with delayed toxicity within the last 4 weeks. Chemotherapy&#xD;
             regimens given continuously or on a weekly basis with limited potential or delayed&#xD;
             toxicity within the last 2 weeks.&#xD;
&#xD;
          7. No concurrent systemic chemotherapy or biologic therapy is allowed.&#xD;
&#xD;
          8. Known human immunodeficiency virus (HIV) or Hepatitis B or C (active, previously&#xD;
             treated or both).&#xD;
&#xD;
          9. History of solid organ transplantation.&#xD;
&#xD;
         10. Psychiatric disorder or social or geographic situation that would preclude study&#xD;
             participation.&#xD;
&#xD;
         11. Known unsuitability for treatment with carboplatin including renal disease where there&#xD;
             is impaired glomerular filtration rate (GFR).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graham Kelly</last_name>
    <role>Study Director</role>
    <affiliation>Noxopharm Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academician Z.Tskhakaia West Georgia National Center of Interventional Medicine&quot; LTD/ Oncology Unit- JSC &quot;EVEX Medical Corporation&quot; group member</name>
      <address>
        <city>Kutaisi</city>
        <zip>4600</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tbilisi State Medical University's First University Clinic, Department Of Oncology</name>
      <address>
        <city>Tbilisi</city>
        <zip>0141</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD, Medulla Chemotherapy and Immunotherapy Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSC, Neo Medi</name>
      <address>
        <city>Tbilisi</city>
        <zip>0313</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 18, 2016</study_first_submitted>
  <study_first_submitted_qc>October 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2016</study_first_posted>
  <results_first_submitted>October 1, 2019</results_first_submitted>
  <results_first_submitted_qc>May 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 2, 2021</results_first_posted>
  <last_update_submitted>May 30, 2021</last_update_submitted>
  <last_update_submitted_qc>May 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for primary and secondary outcome measure will be made available within 12 months after study completion</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>12-18 months after study completion</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT02941523/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT02941523/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NOX66 400 mg</title>
          <description>NOX66 400 mg administered daily for 14 days in a 21-day monotherapy (period 1) followed by 28-day combination therapy cycle (period 2) whereby NOX66 administered on days 1 to 7 and IV carboplatin on Day 2 in each cycle with 2 carboplatin doses low dose carboplatin AUC = 4 for treatment cycles 1-3 followed by higher dose carboplatin AUC = 6 for treatment cycles 4-6.</description>
        </group>
        <group group_id="P2">
          <title>NOX66 800 mg</title>
          <description>NOX66 800 mg administered daily for 14 days in a 21-day monotherapy (period 1) followed by 28-day combination therapy cycle (period 2) whereby NOX66 administered on days 1 to 7 and IV carboplatin on Day 2 in each cycle with 2 carboplatin doses low dose carboplatin AUC = 4 for treatment cycles 1-3 followed by higher dose carboplatin AUC = 6 for treatment cycles 4-6.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Monotherapy</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8">8 received NOX66 400 mg monotherapy and combination therapy with carboplatin.</participants>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Carboplatin Combination Therapy</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8">All continued to combination therapy</participants>
                <participants group_id="P2" count="10">7 continued to combination therapy; 3 started combination therapy only</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Enrolled population = 19 Safety population includes those that received at least 1 NOX66 dose = 18 (n=8 in 400 mg arm; n=10 in 800 mg arm) Efficacy population = 14 (n=5 in 400 mg arm; n=9 in 800 mg arm)</population>
      <group_list>
        <group group_id="B1">
          <title>NOX66 400 mg</title>
          <description>NOX66 400 mg administered daily for 14 days in a 21-day monotherapy (period 1) followed by 28-day combination therapy cycle (period 2) whereby NOX66 administered on days 1 to 7 and IV carboplatin on Day 2 in each cycle with 2 carboplatin doses low dose carboplatin AUC = 4 for treatment cycles 1-3 followed by higher dose carboplatin AUC = 6 for treatment cycles 4-6.</description>
        </group>
        <group group_id="B2">
          <title>NOX66 800 mg</title>
          <description>NOX66 800 mg administered daily for 14 days in a 21-day monotherapy (period 1) followed by 28-day combination therapy cycle (period 2) whereby NOX66 administered on days 1 to 7 and IV carboplatin on Day 2 in each cycle with 2 carboplatin doses low dose carboplatin AUC = 4 for treatment cycles 1-3 followed by higher dose carboplatin AUC = 6 for treatment cycles 4-6.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Georgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experience Dose Limiting Toxicity (DLT) During NOX66 Monotherapy and During NOX66 Combination With Carboplatin</title>
        <description>Dose limiting toxicity during monotherapy and combination therapy defined as any Grade 3 or more toxicity (by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE version 4.03]) (related to therapy) excluding Grade 3 or more neutropenia lasting greater than 5 days or thrombocytopenia associate with bleeding or Grade 4 thrombocytopenia.</description>
        <time_frame>Up to 1 month for NOX66 monotherapy from enrollment and up to 7 months from start of NOX66 combination therapy</time_frame>
        <population>All participants that received at least one dose of NOX66; 3 participants in 800 mg group did not receive monotherapy</population>
        <group_list>
          <group group_id="O1">
            <title>NOX66 400 mg Monotherapy</title>
            <description>NOX66 400 mg administered daily for 14 days in a 21-day monotherapy (period 1)</description>
          </group>
          <group group_id="O2">
            <title>NOX66 400 mg Combination Therapy</title>
            <description>NOX66 400 mg administered daily for 14 days in a 21-day monotherapy (period 1) followed by 28-day combination therapy cycle (period 2) whereby NOX66 administered on days 1 to 7 and IV carboplatin on Day 2 in each cycle with 2 carboplatin doses low dose carboplatin AUC = 4 for treatment cycles 1-3 followed by higher dose carboplatin AUC = 6 for treatment cycles 4-6.</description>
          </group>
          <group group_id="O3">
            <title>NOX66 800 mg Monotherapy</title>
            <description>NOX66 800 mg administered daily for 14 days in a 21-day monotherapy (period 1)</description>
          </group>
          <group group_id="O4">
            <title>NOX66 800 mg Combination Therapy</title>
            <description>NOX66 800 mg administered daily for 14 days in a 21-day monotherapy (period 1) followed by 28-day combination therapy cycle (period 2) whereby NOX66 administered on days 1 to 7 and IV carboplatin on Day 2 in each cycle with 2 carboplatin doses low dose carboplatin AUC = 4 for treatment cycles 1-3 followed by higher dose carboplatin AUC = 6 for treatment cycles 4-6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experience Dose Limiting Toxicity (DLT) During NOX66 Monotherapy and During NOX66 Combination With Carboplatin</title>
          <description>Dose limiting toxicity during monotherapy and combination therapy defined as any Grade 3 or more toxicity (by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE version 4.03]) (related to therapy) excluding Grade 3 or more neutropenia lasting greater than 5 days or thrombocytopenia associate with bleeding or Grade 4 thrombocytopenia.</description>
          <population>All participants that received at least one dose of NOX66; 3 participants in 800 mg group did not receive monotherapy</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Treatment Emergent Adverse Events (SAEs) Related to NOX66.</title>
        <description>An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug that were absent before treatment or that worsened relative to pre-treatment state. Treatment-related are events which had causal relationship to study drug as assessed by the Investigator and were suspected to be reasonably related to the study drug.</description>
        <time_frame>From enrollment through 30 days after the last cycle of therapy (8 months)</time_frame>
        <population>Safety analyses set included all enrolled participants who received at least 1 dose of NOX66 or 1 dose NOX66 and carboplatin.</population>
        <group_list>
          <group group_id="O1">
            <title>NOX66 400 mg Monotherapy</title>
            <description>NOX66 400 mg administered daily for 14 days in a 21-day monotherapy (period 1)</description>
          </group>
          <group group_id="O2">
            <title>NOX66 400 mg Combination Therapy</title>
            <description>NOX66 400 mg administered daily for 14 days in a 21-day monotherapy (period 1) followed by 28-day combination therapy cycle (period 2) whereby NOX66 administered on days 1 to 7 and IV carboplatin on Day 2 in each cycle with 2 carboplatin doses low dose carboplatin AUC = 4 for treatment cycles 1-3 followed by higher dose carboplatin AUC = 6 for treatment cycles 4-6.</description>
          </group>
          <group group_id="O3">
            <title>NOX66 800 mg Monotherapy</title>
            <description>NOX66 800 mg administered daily for 14 days in a 21-day monotherapy (period 1)</description>
          </group>
          <group group_id="O4">
            <title>NOX66 800 mg Combination Therapy</title>
            <description>NOX66 800 mg administered daily for 14 days in a 21-day monotherapy (period 1) followed by 28-day combination therapy cycle (period 2) whereby NOX66 administered on days 1 to 7 and IV carboplatin on Day 2 in each cycle with 2 carboplatin doses low dose carboplatin AUC = 4 for treatment cycles 1-3 followed by higher dose carboplatin AUC = 6 for treatment cycles 4-6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Treatment Emergent Adverse Events (SAEs) Related to NOX66.</title>
          <description>An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug that were absent before treatment or that worsened relative to pre-treatment state. Treatment-related are events which had causal relationship to study drug as assessed by the Investigator and were suspected to be reasonably related to the study drug.</description>
          <population>Safety analyses set included all enrolled participants who received at least 1 dose of NOX66 or 1 dose NOX66 and carboplatin.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR) at Cycle 3 and at Cycle 6 of Combination Therapy</title>
        <description>Objective response rate defined as the percentage of participants achieving a complete response (CR) and or partial response (PR) after treatment with NOX66 and carboplatin therapy as assessed by Response Evaluation Criteria in solid tumors (RECIST) v1.1.&#xD;
CR defined as disappearance of all target and non-target lesions and reduction of any pathological lymph nodes (whether target or non-target) to &lt;10 mm in short axis; PR was defined by a 30% or more decrease in sum of longest diameter (SLD) of target lesions in reference to baseline. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and no new lesions.</description>
        <time_frame>Radiological evaluation at baseline and at 3 months and at 6 months</time_frame>
        <population>Participants with measurable disease by RECIST v1.1 criteria at baseline and at 3 and 6 month post start of combination therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>NOX66 400 mg + Carboplatin (AUC4) to Cycle 3</title>
            <description>NOX66 400 mg administered daily for 14 day in a 21-day monotherapy (period 1) followed by 28-day combination therapy cycle (period 2) whereby NOX66 administered on days 1 to 7 and IV carboplatin on Day 2 in each cycle with low dose carboplatin AUC = 4 for treatment cycles 1-3</description>
          </group>
          <group group_id="O2">
            <title>NOX66 400 mg + Carboplatin (AUC6) to Cycle 6</title>
            <description>NOX66 400 mg administered daily for 14 day in a 21-day monotherapy (period 1) followed by 28-day combination therapy cycle (period 2) whereby NOX66 administered on days 1 to 7 and IV carboplatin on Day 2 in each cycle with 2 carboplatin doses low dose carboplatin AUC = 4 for treatment cycles 1-3 followed by higher dose carboplatin AUC = 6 for treatment cycles 4-6.</description>
          </group>
          <group group_id="O3">
            <title>NOX66 800 mg + Carboplatin (AUC4) to Cycle 3</title>
            <description>NOX66 800 mg administered daily for 14 day in a 21-day monotherapy (period 1) followed by 28-day combination therapy cycle (period 2) whereby NOX66 administered on days 1 to 7 and IV carboplatin on Day 2 in each cycle with low dose carboplatin AUC = 4 for treatment cycles 1-3</description>
          </group>
          <group group_id="O4">
            <title>NOX66 800 mg + Carboplatin (AUC6) to Cycle 6</title>
            <description>NOX66 800 mg administered daily for 14 day in a 21-day monotherapy (period 1) followed by 28-day combination therapy cycle (period 2) whereby NOX66 administered on days 1 to 7 and IV carboplatin on Day 2 in each cycle with 2 carboplatin doses low dose carboplatin AUC = 4 for treatment cycles 1-3 followed by higher dose carboplatin AUC = 6 for treatment cycles 4-6.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR) at Cycle 3 and at Cycle 6 of Combination Therapy</title>
          <description>Objective response rate defined as the percentage of participants achieving a complete response (CR) and or partial response (PR) after treatment with NOX66 and carboplatin therapy as assessed by Response Evaluation Criteria in solid tumors (RECIST) v1.1.&#xD;
CR defined as disappearance of all target and non-target lesions and reduction of any pathological lymph nodes (whether target or non-target) to &lt;10 mm in short axis; PR was defined by a 30% or more decrease in sum of longest diameter (SLD) of target lesions in reference to baseline. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and no new lesions.</description>
          <population>Participants with measurable disease by RECIST v1.1 criteria at baseline and at 3 and 6 month post start of combination therapy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Clinical Response Rate at Cycle 3 and at Cycle 6 of Combination Therapy</title>
        <description>Overall Clinical response rate defined as the percentage of participants who achieved complete response (CR) or partial response (PR) or stable disease (SD) as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) criteria v1.1 after combination of NOX66 and carboplatin therapy.&#xD;
CR defined as disappearance of all target and non-target lesions and reduction of any pathological lymph nodes (whether target or non-target) to &lt;10 mm in short axis; PR was defined by a 30% or more decrease in sum of longest diameter (SLD) of target lesions in reference to baseline. Stable disease (SD)=Neither sufficient increase to qualify for PD nor sufficient shrinkage to qualify for PR. PD was defined as at least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.</description>
        <time_frame>Radiological evaluation at baseline and at 3 months and at 6 months</time_frame>
        <population>Participants with evaluable (measurable ) disease by RECIST v1.1 criteria at baseline and at 3 month and 6 month post combination therapy</population>
        <group_list>
          <group group_id="O1">
            <title>NOX66 400 mg + Carboplatin (AUC4) to Cycle 3</title>
            <description>NOX66 400 mg administered daily for 14 day in a 21-day monotherapy (period 1) followed by 28-day combination therapy cycle (period 2) whereby NOX66 administered on days 1 to 7 and IV carboplatin on Day 2 in each cycle with low dose carboplatin AUC = 4 for treatment cycles 1-3</description>
          </group>
          <group group_id="O2">
            <title>NOX66 400 mg + Carboplatin (AUC6) to Cycle 6</title>
            <description>NOX66 400 mg administered daily for 14 day in a 21-day monotherapy (period 1) followed by 28-day combination therapy cycle (period 2) whereby NOX66 administered on days 1 to 7 and IV carboplatin on Day 2 in each cycle with 2 carboplatin doses low dose carboplatin AUC = 4 for treatment cycles 1-3 followed by higher dose carboplatin AUC = 6 for treatment cycles 4-6.</description>
          </group>
          <group group_id="O3">
            <title>NOX66 800 mg + Carboplatin (AUC4) to Cycle 3</title>
            <description>NOX66 800 mg administered daily for 14 day in a 21-day monotherapy (period 1) followed by 28-day combination therapy cycle (period 2) whereby NOX66 administered on days 1 to 7 and IV carboplatin on Day 2 in each cycle with low dose carboplatin AUC = 4 for treatment cycles 1-3</description>
          </group>
          <group group_id="O4">
            <title>NOX66 800 mg + Carboplatin (AUC6) to Cycle 6</title>
            <description>NOX66 800 mg administered daily for 14 day in a 21-day monotherapy (period 1) followed by 28-day combination therapy cycle (period 2) whereby NOX66 administered on days 1 to 7 and IV carboplatin on Day 2 in each cycle with 2 carboplatin doses low dose carboplatin AUC = 4 for treatment cycles 1-3 followed by higher dose carboplatin AUC = 6 for treatment cycles 4-6.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Clinical Response Rate at Cycle 3 and at Cycle 6 of Combination Therapy</title>
          <description>Overall Clinical response rate defined as the percentage of participants who achieved complete response (CR) or partial response (PR) or stable disease (SD) as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) criteria v1.1 after combination of NOX66 and carboplatin therapy.&#xD;
CR defined as disappearance of all target and non-target lesions and reduction of any pathological lymph nodes (whether target or non-target) to &lt;10 mm in short axis; PR was defined by a 30% or more decrease in sum of longest diameter (SLD) of target lesions in reference to baseline. Stable disease (SD)=Neither sufficient increase to qualify for PD nor sufficient shrinkage to qualify for PR. PD was defined as at least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.</description>
          <population>Participants with evaluable (measurable ) disease by RECIST v1.1 criteria at baseline and at 3 month and 6 month post combination therapy</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Monotherapy Phase, NOX66 400 mg</title>
          <description>NOX66 400 mg administered daily for 14 day in a 21-day monotherapy phase (period 1)</description>
        </group>
        <group group_id="E2">
          <title>Monotherapy Phase, NOX66 800 mg</title>
          <description>NOX66 800 mg administered daily for 14 day in a 21-day monotherapy phase (period 1)</description>
        </group>
        <group group_id="E3">
          <title>Combination Phase, NOX66 400 mg</title>
          <description>Up to 6 cycles of a 28-day combination therapy cycle (period 2) with NOX66 400 mg administered daily on days 1 to 7 and IV carboplatin administered on Day 2 in each cycle with 2 carboplatin doses - low dose carboplatin AUC = 4 for treatment cycles 1-3 followed by higher dose carboplatin AUC = 6 for treatment cycles 4-6.</description>
        </group>
        <group group_id="E4">
          <title>Combination Phase, NOX66 800 mg</title>
          <description>Up to 6 cycles of a 28-day combination therapy cycle (period 2) with NOX66 800 mg administered daily on days 1 to 7 and IV carboplatin administered on Day 2 in each cycle with 2 carboplatin doses - low dose carboplatin AUC = 4 for treatment cycles 1-3 followed by higher dose carboplatin AUC = 6 for treatment cycles 4-6.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>haemorrhage</sub_title>
                <description>intestinal bleed</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>sudden death</sub_title>
                <description>sudden death</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion reaction</sub_title>
                <description>related to carboplatin infusion</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA PT</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="7" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain, upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neuropathy, peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism, arterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to Phase 1 nature of the study, the subject sample size was small.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Manager</name_or_title>
      <organization>Noxopharm Limited</organization>
      <phone>+61 499005049</phone>
      <email>marinella.messina@noxopharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

